Skip to main content

Theseus Pharmaceuticals Inc(THRX-Q)
NASDAQ

Today's Change
Delayed Last Update

Theseus Pharmaceuticals Announces Business Highlights and Reports Second Quarter 2023 Financial Results

PR Newswire - Thu Aug 10, 2023

IND submission for THE-349 in EGFR-mutant NSCLC expected in Q4 2023

Development candidate nomination for BCR-ABL program in CML and Ph+ ALL expected in H1 2024

Read more at prnewswire.com

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe